DaVita Inc. (NYSE:DVA) Receives $162.80 Average Price Target from Brokerages

DaVita Inc. (NYSE:DVAGet Free Report) has been assigned an average recommendation of “Hold” from the five research firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and one has issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $162.80.

Separately, Barclays raised their price objective on shares of DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a research report on Tuesday.

View Our Latest Analysis on DVA

Institutional Trading of DaVita

Several hedge funds have recently modified their holdings of DVA. Invesco Ltd. grew its stake in shares of DaVita by 20.9% in the 4th quarter. Invesco Ltd. now owns 1,589,545 shares of the company’s stock worth $237,716,000 after buying an additional 275,284 shares in the last quarter. Northern Trust Corp grew its position in DaVita by 12.5% in the 4th quarter. Northern Trust Corp now owns 740,774 shares of the company’s stock valued at $110,783,000 after acquiring an additional 82,326 shares during the last quarter. JPMorgan Chase & Co. increased its stake in DaVita by 17.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock worth $99,846,000 after buying an additional 92,014 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in DaVita by 14.0% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 466,046 shares of the company’s stock worth $69,697,000 after acquiring an additional 57,386 shares in the last quarter. Finally, Amundi increased its position in shares of DaVita by 116.4% during the fourth quarter. Amundi now owns 446,386 shares of the company’s stock worth $68,726,000 after acquiring an additional 240,126 shares during the period. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Trading Down 5.8 %

DaVita stock opened at $145.99 on Tuesday. DaVita has a one year low of $119.42 and a one year high of $179.60. The business’s fifty day moving average is $161.24 and its 200 day moving average is $157.81. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. The stock has a market capitalization of $11.68 billion, a PE ratio of 13.59, a price-to-earnings-growth ratio of 1.01 and a beta of 0.94.

DaVita (NYSE:DVAGet Free Report) last announced its earnings results on Thursday, February 13th. The company reported $2.24 EPS for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. On average, sell-side analysts predict that DaVita will post 10.72 EPS for the current year.

DaVita Company Profile

(Get Free Report

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Featured Stories

Analyst Recommendations for DaVita (NYSE:DVA)

Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.